Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective

2012 ◽  
Vol 3 (2) ◽  
pp. 195-208 ◽  
Author(s):  
Margaret S Landis ◽  
Tracey Boyden ◽  
Simon Pegg
Keyword(s):  
Drug Delivery ◽  
Cns Drug Delivery

Nanocarriers as CNS Drug Delivery Systems for Enhanced Neuroprotection

2017 ◽  
pp. 33-55 ◽  
Author(s):  
Asya Ozkizilcik ◽  
Parker Davidson ◽  
Hulusi Turgut ◽  
Hari S. Sharma ◽  
Aruna Sharma ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Cns Drug Delivery

scholarly journals NanoART, neuroAIDS and CNS drug delivery

Nanomedicine ◽  
2009 ◽  
Vol 4 (5) ◽  
pp. 557-574 ◽  
Author(s):  
Ari Nowacek ◽  
Howard E Gendelman
Keyword(s):  
Drug Delivery ◽  
Cns Drug Delivery

The use of microdialysis in CNS drug delivery studies

2000 ◽  
Vol 45 (2-3) ◽  
pp. 283-294 ◽  
Author(s):  
Margareta Hammarlund-Udenaes
Keyword(s):  
Drug Delivery ◽  
Cns Drug Delivery

Abstract 6251: Blood brain barrier opening by TTFields: a future CNS drug delivery strategy

2020 ◽  
Author(s):  
Ellaine Salvador ◽  
Almuth F. Kessler ◽  
Julia Hörmann ◽  
Malgorzata Burek ◽  
Catherine T. Brami ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Delivery Strategy ◽  
Cns Drug Delivery ◽  
Blood Brain ◽  
Barrier Opening ◽  
Blood Brain Barrier Opening

scholarly journals Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin

Molecules ◽  
2020 ◽  
Vol 25 (21) ◽  
pp. 5188
Author(s):  
Toshihiko Tashima
Keyword(s):  
Drug Delivery ◽  
Olfactory Epithelium ◽  
Olfactory Nerve ◽  
Brain Drug Delivery ◽  
Cns Drug Delivery ◽  
Capillary Endothelial Cells ◽  
Alternative Approaches ◽  
Cns Drugs ◽  
Direct Delivery ◽  
The Brain

The direct delivery of central nervous system (CNS) drugs into the brain after administration is an ideal concept due to its effectiveness and non-toxicity. However, the blood–brain barrier (BBB) prevents drugs from penetrating the capillary endothelial cells, blocking their entry into the brain. Thus, alternative approaches must be developed. The nasal cavity directly leads from the olfactory epithelium to the brain through the cribriform plate of the skull bone. Nose-to-brain drug delivery could solve the BBB-related repulsion problem. Recently, it has been revealed that insulin improved Alzheimer’s disease (AD)-related dementia. Several ongoing AD clinical trials investigate the use of intranasal insulin delivery. Related to the real trajectory, intranasal labeled-insulins demonstrated distribution into the brain not only along the olfactory nerve but also the trigeminal nerve. Nonetheless, intranasally administered insulin was delivered into the brain. Therefore, insulin conjugates with covalent or non-covalent cargos, such as AD or other CNS drugs, could potentially contribute to a promising strategy to cure CNS-related diseases. In this review, I will introduce the CNS drug delivery approach into the brain using nanodelivery strategies for insulin through transcellular routes based on receptor-mediated transcytosis or through paracellular routes based on escaping the tight junction at the olfactory epithelium.

scholarly journals Hypoxia/Reoxygenation Stress Signals an Increase in Organic Anion Transporting polypeptide 1a4 (Oatp1a4) at the Blood–Brain Barrier: Relevance to CNS Drug Delivery

2014 ◽  
Vol 34 (4) ◽  
pp. 699-707 ◽  
Author(s):  
Brandon J Thompson ◽  
Lucy Sanchez-Covarrubias ◽  
Lauren M Slosky ◽  
Yifeng Zhang ◽  
Mei-li Laracuente ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Blood Brain Barrier ◽  
Transforming Growth Factor ◽  
Organic Anion ◽  
Functional Expression ◽  
Brain Barrier ◽  
Parp Cleavage ◽  
Organic Anion Transporting Polypeptide ◽  
Cns Drug Delivery ◽  
Blood Brain

Cerebral hypoxia and subsequent reoxygenation stress (H/R) is a component of several diseases. One approach that may enable neural tissue rescue after H/R is central nervous system (CNS) delivery of drugs with brain protective effects such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (i.e., statins). Our present in vivo data show that atorvastatin, a commonly prescribed statin, attenuates poly (ADP-ribose) polymerase (PARP) cleavage in the brain after H/R, suggesting neuroprotective efficacy. However, atorvastatin use as a CNS therapeutic is limited by poor blood–brain barrier (BBB) penetration. Therefore, we examined regulation and functional expression of the known statin transporter organic anion transporting polypeptide 1a4 (Oatp1a4) at the BBB under H/R conditions. In rat brain microvessels, H/R (6% O2, 60 minutes followed by 21% O2, 10 minutes) increased Oatp1a4 expression. Brain uptake of taurocholate (i.e., Oap1a4 probe substrate) and atorvastatin were reduced by Oatp inhibitors (i.e., estrone-3-sulfate and fexofenadine), suggesting involvement of Oatp1a4 in brain drug delivery. Pharmacological inhibition of transforming growth factor- β (TGF- β)/activin receptor-like kinase 5 (ALK5) signaling with the selective inhibitor SB431542 increased Oatp1a4 functional expression, suggesting a role for TGF- β/ALK5 signaling in Oatp1a4 regulation. Taken together, our novel data show that targeting an endogenous BBB drug uptake transporter (i.e., Oatp1a4) may be a viable approach for optimizing CNS drug delivery for treatment of diseases with an H/R component.

scholarly journals The Promise and Perils of CNS Drug Delivery: A Video Debate

2008 ◽  
Vol 3 (2) ◽  
pp. 58-58 ◽  
Author(s):  
Howard E. Gendelman ◽  
Alexander Kabanov ◽  
James Linder
Keyword(s):  
Drug Delivery ◽  
Cns Drug Delivery
Sign in / Sign up

Export Citation Format

Share Document